Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon Jan 17, 2020 11:54am
185 Views
Post# 30565352

Annonymous sued

Annonymous sued

ORONTO - A dozen individuals have been ordered to pay thousands of dollars in damages for defamatory statements they made in an internet chat forum, even though the plaintiffs don't know who they are and collecting will likely prove difficult.

The judgment in Ontario Superior Court of Justice comes despite the difficulties in suing people who post inflammatory comments anonymously, and who then fail to respond to the resulting legal proceedings against them.

What it does make clear, however, is that anonymity and failure to respond do not necessarily preclude a case from proceeding, or a court from awarding damages.

 

"If people want to make hurtful statements about others and then try to hide from the responsibility to prove the truth or other justification for doing so ... their cowardice is reprehensible," Justice Frederick Myers said in his judgment released Monday.

The defamatory comments were posted in 2014 and 2015 on the investor-oriented Bullboard message forum on the website stockhouse.com. They were directed at Toronto-based Theralase Technologies Inc., a publicly traded pharmaceutical company, and its principals, Roger Dumoulin-White and spouse, Kristina Hachey.

Essentially, the posts criticize them both professionally and personally, accusing them among other things of lying and illegal behaviour.

"Roger is like a pest diseased dog spreading his filthy rabbies (sic)," the user Nastynasta wrote. "A mangy dog that won't go away until he's put down."

"The management team are liars!!!" TrueNorthStrong wrote. "Been lying for 21 years!!"

Hachey was also the object of at least one "disgusting" misogynistic post that had nothing to do with investor complaints, the judge found.

Stockhouse.com said it was unable to give the real identities of the posters to the plaintiffs. However it did provide email addresses, allowing the plaintiffs to serve the lawsuit.

The court ruled the service by email and, in some cases, by private messages via stockhouse.com was good enough to assume the posters were aware of the proceedings, and allow the case to go ahead.

Only one defendant responded; the case against him is ongoing. The other defendants — including one person who has since been identified as a former disgruntled Theralase employee — were noted in default.

Bullboard Posts